Effects of a gonadotropin-releasing hormone agonist on rat ovarian adenocarcinoma cell lines in vitro and in vivo

Japanese Journal of Cancer Research

Volumn 89, Issue 9, 1998, Pages 977-984

  Maruuchi, Tatsuhiro ^a   Sugiyama, Toru ^a   Kataoka, Akio ^a   Nishida, Takashi ^a   Yakushiji, Michiaki ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

GnRH agonist; In vitro; In vivo; Ovarian cancer; Rat

Indexed keywords

7,12 DIMETHYLBENZ[A]ANTHRACENE; BUSERELIN; FOLLITROPIN; GONADORELIN AGONIST; LUTEINIZING HORMONE; PROGESTERONE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CELL DEATH; CELL PROLIFERATION; CONNECTIVE TISSUE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; FOLLITROPIN RELEASE; INTRAMUSCULAR DRUG ADMINISTRATION; LUTEINIZING HORMONE RELEASE; NONHUMAN; OVARY ADENOCARCINOMA; PRIORITY JOURNAL; PROGESTERONE RELEASE; RAT;

EID: 0031734024     PISSN: 09105050     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1349-7006.1998.tb00657.x     Document Type: Article

References (38)

1. Boring, C. C., Squires, T. S. and Tong, T. Cancer statistics, 1991. CA Cancer J. Clin., 41, 19-36 (1991).
2. Ozols, R. F., Rubin, S. C. and Dembo, A. J. Epithelial ovarian cancer. In "Principles of Gynaecologic Oncology," ed. W. J. Hoskins, C. A. Perez, and R. C. Young, pp. 731-781 (1992). Lippincott, Philadelphia, PA.
3. Trimble, E. L., Adams, J. D., Vena, D., Hawkins, M. J., Friedman, M. A., Fisherman, J. S., Christian, M. C., Canetta, R., Onetto, N., Hayn, R. and Arbuck, S. G. Paclitaxel for platinum-refractory ovarian cancer: results from the first 1,000 patients registered to National Cancer Institute Treatment Referral Center 9103. J. Clin. Oncol., 11, 2405-2410 (1993).
4. Scott, J. S. How to induce: and how not to. Br. Med. J., 289, 781-782 (1984).
5. Kammerman, S., Demopoulos, R. I., Raphael, C. and Ross J. Gonadotropic hormone binding to human ovarian tumors. Hum. Pathol., 12, 886-890 (1981).
6. Emons, G., Pahwa, G. S., Brack, C., Sturm, R., Oberheuserm, F. and Knupper R. Gonadotropin releasing hormone binding sites in human epithelial ovarian carcinoma. Eur. J. Cancer Clin. Oncol., 25, 215-221 (1989).
7. Biskind, M. S. and Biskind, G. S. Development of tumors in the rat ovary after transplantation into the spleen. Proc. Soc. Exp. Biol. Med., 55, 176-179 (1944).
8. Motel, R., Satyaswaroop, P. G., Schally, A. V., Hamilton, T. and Ozols, R. Inhibitory effect of GnRH. superagonist on the growth of human ovarian carcinoma. NIH; OV-CAR 3 in the nude mouse. Gynecol. Oncol., 23, 254-255 (1986).
9. Peterson, C. M. and Zimniski, S. J. A long acting gonadotropin-releasing hormone agonist inhibits the growth of a human ovarian epithelial carcinoma (BG-1) heterotransplanted in the nude mouse. Obstet. Gynecol. 76, 264-267 (1990).
10. 6-LH-RH; a preliminary report. Cancer Lett., 41, 105-110 (1988).
11. Ohtani, K., Sakamoto, H. and Den, K. Antagonistic effects of GnRH agonist on gonadotropin-stimulated proliferation of human ovarian cell line. In "GnRH Analogues and Cancer," Vol. 4, pp. 83-85 (1992). The Parthenon Publishing Group Ltd., New Jersey.
12. Klijn, J. M. L. and De Jong, F. H. Treatment with a luteinizing hormone-releasing hormone analogue (buserelin) in premenopausal patients with metastatic breast cancer. Lancet, i, 1213-1216 (1982).
13. Kaufmann, M., Jonat, W., Kleeberg, U., Eiermann, W., Janicke, F., Hilfrich, J., Kreienberg, R., Albrecht, M., Weitzel, H. K., Schmid, H., Strunz, P., Schachner-Wunschmann, E., Basiert, G. and Maass, H. for the German Zoladex Trial Group. Goserelin, a depot gonadotropin-releasing hormone agonist in the treatment of premenopausal patients with metastatic breast cancer. J. Clin. Oncol., 7, 1113-1119 (1989).
14. Presant, C. A., Soloway, M. S., Klioze, S. S., Kosola, J. W., Yakabow, A. L., Mendez, R. G., Kennedy, P. S., Wyres, M. R., Naessig, V. L. and Ford, K. S. Buserelin as primary therapy in advanced prostate carcinoma. Cancer, 56, 2416-2419 (1985).
15. Jager, W., Wildt, L. and Lang, N. Some observations on the effects of a GnRH analogue in ovarian cancer. Eur. J. Obstet. Gynecol. Reprod. Biol., 32, 137-148 (1989).
16. Parmar, H., Phillips, R. H., Rustin, G., Lightman, S. L. and Schally, A. V. Therapy of advanced ovarian cancer with D-Trp-6-LH-RH (decapeptyl) microcapsules. Biomed. Pharmacother., 42, 531-538 (1988).
17. Kavanagh, J. J., Roberts, W., Townsend, P. and Hewitt, S. Leuprolide acetate in the treatment of refractory or persistent epithelial ovarian cancer. J. Clin. Oncol., 7, 115-118 (1989).
18. Scambia, G., Benedetti Panici, P., Greggi, S., Baiocchi, G., Perrone, L. and Mancuso, S. Phase II study with an LH-RH analogue in advanced ovarian cancer. J. Gynecol. Endocrinol., VI (No. 1-4), 5-7 (1990).
19. Falkson, C. I., Falkson, H. C. and Falkson, G. Cisplatin versus cisplatin plus D-Trp-6-LHRH in the treatment of ovarian cancer: a pilot trial to investigate the effect of the addition of a GnRH analogue to cisplatin. Oncology, 53, 313-317 (1996).
20. Sugiyama, T., Nishida, T., Nakanami, M., Ushijima, K., Shibue, K., Katabuchi, H., Yakushiji, M. and Kato, T. Characterization of transplant generations of primary rat adenocarcinoma and some chemotherapeutic observations. Acta Obstet. Gynaecol. Jpn., 37, 681-686 (1987).
21. Kataoka, A., Kojiro, M., Yakushiji, M., Nishida, T. and Kato, T. Establishment and morphologic characterization of cell line (DMBA-OC-1) from 7, 12-dimethylbenz(a)anthracene-induced rat ovarian carcinoma. Acta Obstet. Gynaecol. Jpn., 37, 842-848 (1987).
22. Galli, M. C., De Giovanni, C., Nicoletti, G., Grilli, S., Nanni, P., Prodi, G., Gola, G., Rocchetta, R. and Orlandi, C. The occurrence of multiple steroid hormone receptors in disease-free and neoplastic human ovary. Cancer, 47, 1297-1302 (1981).
23. Vilcek, J., Palombella, V. J., Henriksen-DeStefano, D., Swenton, C., Feinman, R., Hirai, M. and Tsujimoto, M. Fibroblast growth-enhancing activity of tumor necrosis factor and its relationship to other polypeptide growth factors. J. Exp. Med., 168, 187-192 (1986).
24. Harwood, J. P., Clayton, R. N., Chen, T. T., Knox, G. and Catt, K. J. Ovarian gonadotropin-releasing hormone receptor. II. Regulation and effects on ovarian development. Endocrinology, 107, 414-421 (1980).
25. Maynard, P. V. and Nicholson, R. I. Effects of high doses of a series of new luteinizing hormone-releasing hormone analogues in intact female rats. Br. J. Cancer, 39, 274-279 (1979).
26. Peterson, C. M., Jolles, C. J., Carrell, D. T., Straight, R. C., Jones, K. P., Poulson, A. M., Jr. and Hatasaka, H. H. GnRH agonist therapy in human ovarian epithelial carcinoma (OVCAR-3) heterotransplanted in the nude mouse is characterized by latency and transience. Gynecol. Oncol., 52, 26-30 (1994).
27. Imai, A., Iida, K. and Tamaya, T. Gonadotropin-releasing hormone has a biphasic action on aromatase activity through protein kinase C in granulosa cell tumor. Int. J. Fertil., 38, 50-56 (1993).
28. Wimalasena, J., Dostal, R. and Meehan D. Gonadotropins, estradiol, and growth factors regulate epithelial ovarian cancer cell growth. Gynecol. Oncol., 46, 345-350 (1992).
29. Kataoka, A., Nishida, T., Motomura, S., Higashijima, T., Ueyama, T., Sugiyama, T. and Yakushiji, M. The effect of sex steroid hormones, gonadotropins, and gonadotropin releasing hormone agonist on the proliferation of ovarian cancer cell line (KOC-2S). Acta Obstet. Gynaecol. Jpn., 46, 1033-1040 (1994).
30. Slotman, B. J., Poels, L. G. and Rao, B. R. A direct LHRH-agonist action on cancer cells is unlikely to be the cause of response to LHRH-agonist treatment. Anticancer Res., 9, 77-80 (1989).
31. Connor, J. P., Buller, R. E. and Conn, P. M. Effects of GnRH analogs on six ovarian cancer cell lines in culture. Gynecol. Oncol., 54, 80-86 (1994).
32. Miller, W. R., Scott, W. N., Morris, R., Fraser, H. M. and Sharpe, R. M. Growth of human breast cancer cells inhibited by a luteinizing hormone-releasing hormone agonist. Nature, 313, 231-233 (1985).
33. Neri, C., Berthois, Y., Schatz, B., Drieu, K. and Martin, P. M. Compared effects of GnRH analogues and 4-hydroxytamoxifen on growth and steroid receptors in antiestrogen sensitive and resistant MCF-7 breast cancer cell sublines. Breast Cancer Res. Treat., 15, 85-93 (1990).
34. Ohtani, K., Sakamoto, H. and Sato, K. Stimulatory effect of follicular stimulating hormone on the proliferation of ovarian cancer cell line in vitro and in vivo. Acta Obstet. Gynaecol. Jpn., 44, 717-724 (1992).
35. Ranta, T., Baukal, A., Knecht, M., Korhonen, M. and Catt, K. J. Inhibitory actions of a gonadotropin-releasing hormone agonist on ovarian follicle stimulating hormone receptors and adenylate cyclase in vivo. Endocrinology, 112, 956-964 (1983).
36. Billig, H., Furuta, I. and Hsueh, J. W. Gonadotropin-releasing hormone directly induces apoptotic cell death in the rat ovary: biochemical and in situ detection of deoxyribonucleic acid fragmentation in granulosa cells. Endocrinology, 134, 245-252 (1994).
37. Emons, G., Ortmann, O., Pahwa, G. S., Hackenberg, R., Oberheuser, F. and Schulz, K.-D. Intracellulur actions of gonadotropic and peptide hormones and the therapeutic value of GnRH-agonists in ovarian cancer. Acta Obstet. Gynecol. Scand., 71 (Suppl.), 31-38 (1992).
38. Motomura, S. Induction of apoptosis in ovarian carcinoma cell line by gonadotropin-releasing hormone agonist. Kurume Med. J., 45, 27-32 (1998).